Emergent BioSolutions Announces Completion of Acquisition of PaxVax for ~$270M

 Emergent BioSolutions Announces Completion of Acquisition of PaxVax for ~$270M

 Shots:

  • The acquisition is focus on development of vaccines for adenovirus types 4 and 7, and expanding the company’s vaccine product portfolio
  • Emergent to pay an upfront ~$270M in cash to get hold of PaxVax’s two marketed vaccines- Vivotif and Vaxchora and pipeline products
  • Vivotif (Typhoid Vaccine Live Oral Ty21a), and Vaxchora (Cholera Vaccine, Live, Oral) are novel vaccines approved by the US FDA for the prevention of typhoid fever and for prevention of cholera respectively

Click here to read full press release/ article | Ref: Emergent Biosolutions  | Image: PaxVax

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post